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Functional genomic analyses provide information
that allows hypotheses to be formulated on protein
function. These hypotheses, however, need to be
validated using reverse genetic approaches, which
are difficult to perform on a large scale and in diploid
organisms. We developed a genetic screen for
isolating ‘‘lariat’’ peptides that function as trans
dominant inhibitors of protein function. A lariat
consists of a lactone-cyclized peptide with a cova-
lently attached transcription activation domain,
which allows combinatorial lariat libraries to be
screened for protein interactions using the yeast
two-hybrid assay. We isolated lariats against the
bacterial repressor protein LexA. LexA regulates
bacterial SOS response and LexA mutants that
cannot undergo autoproteolysis make bacteria
more sensitive to, and inhibit resistance against,
cytotoxic reagents. We showed that an anti-LexA
lariat blocked LexA autoproteolysis and potentiated
the antimicrobial activity of mitomycin C.
INTRODUCTION
Ideal reagents for reverse analysis of protein function in diploid
organisms have a dominant mode of action, are easily and
rapidly generated against any given target, inhibit protein inter-
actions and activities, and block specific interactions with
a protein while leaving other interactions unperturbed. Further,
to demonstrate the therapeutic potential of inhibiting targets
with small molecule drugs, reverse analysis must also be per-
formed with reagents that directly inhibit their target rather
than blocking steps in target transcription or translation. Intracel-
lular inhibitors with these characteristics can be rapidly obtained
by genetically screening conformationally constrained, scaf-
folded peptides (peptide aptamers) from combinatorial peptide
aptamer libraries using the yeast two-hybrid (Y2H) assay (Geyer
and Brent, 2000). Constrained peptides are preferred as they
generally bind tighter (Geyer and Brent, 2000) and are more
stable (Davidson and Sauer, 1994) than linear peptides. The
scaffold protein enhances solubility and allows a transcription
activation domain to be fused to the peptide aptamer, which is1148 Chemistry & Biology 16, 1148–1157, November 25, 2009 ª200essential for the Y2H assay. Combinatorial libraries of peptide
aptamers should in principle contain members that bind any
protein target.
There are several limitations with displaying peptides on the
surface of scaffold proteins. First, some scaffold proteins are
not stable enough to display and constrain a variety of peptides
on their surface. For the green fluorescent protein scaffold, as
many as one-third of peptides destabilize its structure
(Woodman et al., 2005; Abedi et al., 1998). Second, some scaf-
fold proteins are not stably expressed at high levels in a variety of
cell types. For the thioredoxin (TrxA) scaffold, it has been shown
that many TrxA peptide aptamers are not stable in human cell
culture (Woodman et al., 2005). Third, scaffold proteins may
possess intrinsic biological activity that is independent of the
constrained peptide, which makes it difficult to decipher peptide
aptamer activity (Woodman et al., 2005). Fourth, the conforma-
tion of the displayed peptide may be dictated by the location
where the ends of the loop are inserted into the scaffold protein.
Many peptides lose activity when they are transferred to other
peptide scaffolds (Klevenz et al., 2002). Fifth, the size of many
scaffold proteins limits their use as drugs or drug leads as they
are usually not membrane permeable and they are susceptible
to degradation by proteases. Further, the size of the scaffold
prevents their chemical synthesis, makes their structure difficult
to solve, and limits their access to sites on proteins such as
active site crevices.
An alternative method of displaying peptides without many of
the above limitations involves constraining peptides by cycliza-
tion. There are many examples of natural and synthetic cyclic
peptide inhibitors (Horswill and Benkovic, 2005). Recently,
methods have been developed to express genetically encoded
cyclic peptides using engineered inteins (Scott et al., 1999).
Unlike scaffold-constrained peptides, cyclic peptides are dis-
played independently of a scaffold protein, are resistant to exo-
proteases, and are amenable to chemical synthesis, structural
studies, and membrane transport. Combinatorial libraries of
cyclic peptides have been screened using forward and reverse
approaches to isolate cyclic peptides that inhibit cellular
processes (Kinsella et al., 2002; Nilsson et al., 2005; Cheng
et al., 2007; Naumann et al., 2008; Kritzer et al., 2009) and disrupt
protein interactions (Horswill et al., 2004; Tavassoli and Ben-
kovic, 2005; Tavassoli et al., 2008), respectively. It is not
possible, however, to isolate cyclic peptides that interact with
specific proteins using genetic systems such as the Y2H assay,
since there is no N or C terminus to fuse a transcription activation9 Elsevier Ltd All rights reserved
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for the reverse analysis of protein function.
Here, we describe a novel genetic assay to isolate lariat
peptides that interact with a target protein using the Y2H interac-
tion trap (Gyuris et al., 1993). A lariat peptide consists of a cyclic
peptide or ‘‘noose’’ region with a covalently attached transcrip-
tion activation domain. We generated lariats that were compat-
ible with the Y2H assay by blocking the intein-producing cyclic
peptide reaction (Scott et al., 1999) at an intermediate step,which
produces a lariat that contains a transcription activation domain
covalently attached through an amide bond to a lactone-cyclized
peptide. Lariat peptides can be used to study the function or
validate the therapeutic potential of protein targets.
We demonstrate the feasibility of this approach by generating
a lariat inhibitor of the bacterial repressor protein LexA. LexA is
a putative antimicrobial target, which when inhibited should
potentiate the activity of cytotoxic antibiotics. When LexA is
bound by activated RecA it undergoes autoproteolysis and no
longer represses genes in its regulon (Lin and Little, 1988).
LexA mutants that block autoproteolysis (Walker, 1984) make
bacteria more sensitive to stress induced by compounds such
as theDNAdamaging reagentmitomycin C (MMC) (Lin and Little,
1988) and they decrease antibiotic resistance (Cirz et al., 2005;
Miller et al., 2004). LexA inhibitors that block autoproteolysis
would increase the sensitivity of bacteria to cytotoxic reagents
and since LexA is not present in humans it would have no effect
on host DNA damage repair systems.
RESULTS
Construction and Screening of Combinatorial Lariat
Peptide Libraries
To generate the lariat, we blocked the asparagine cyclization
step in the intein-producing cyclic peptide reaction (Scott
et al., 1999) (Figure 1A) by mutating asparagine at position IC-1
to alanine (Figure 1B). We created a combinatorial library of
lariats with the noose region containing the amino acid sequence
SX7EY, where X represents amino acids encoded by the NNK
codon. Glutamate (E) and tyrosine (Y) amino acids in the noose
region were included to facilitate cyclization (Scott et al., 2001;
Naumann et al., 2005). We constructed a lariat peptide expres-
sion plasmid library (pIL-XX) in the MATa yeast strain EY93. To
estimate the number of library members that correctly produced
lariats in yeast, we sequenced randomly chosen librarymembers
and showed that 31% had a correct sequence (see Figure S1
available online). We also analyzed processing of 20 library
members with the correct sequence and showed that 70% of
these library members produced a lariat product by western
analysis (Figure S1). In total, 25% of the library is capable of
producinga lariat.Wemateda library of approximately fivemillion
lariats in the MATa strain EY93 to the MATa strain EY111, which
contains the LexA target plasmid and Y2H reporter genes. We
screened23108MATa/a yeast cells that contain the lariat library,
the LexA target, and Y2H reporter genes using the Y2H interac-
tion trap (Figure 1C) (Finley andBrent, 1994) and isolated 14 posi-
tive interactions based on the activation of the LEU2, ADE2, and
LacZ reporter genes. Sequencing of the 14 positive plasmids re-
vealed 12 plasmidswith the L2 sequence and 2 plasmidswith the
L1 sequence (Figure 1D). We chose the L2 lariat for further anal-Chemistry & Biology 16, 1148–1ysis as it containedmore charged amino acids, whichwe hypoth-
esized would enhance its solubility.
Characterization of Anti-LexA Lariats
To confirm the importance of the lariat structure for the L2 lariat-
LexA interaction, we cloned the noose region of the L2 lariat into
the following modified intein expression plasmids (Figure 2): (1)
L2 inactive intein plasmid (pIN-L2), which expresses a lariat
precursor that does not undergo any steps in the intein-mediated
cyclization reaction; (2) L2 linear plasmid (pLIN-L2), which
expresses an L2 peptide that is not cyclized by a lactone
bond; (3) L2 active intein plasmid (pACT-L2), which expresses
a cyclic L2 peptide; and (4) L2 control lariat plasmids, which
express amino acids from the noose region of the L2 lariat in
a scrambled (pIL-L2-scrambled) or inverted (pIL-L2-inverted)
order. We confirmed expression of these L2 constructs using
western analysis with an antibody against the N-terminal hemag-
glutinin (HA) tag (Figure 3A). The L2 lariat plasmid produced
unprocessed (32 kDa) and lariat (18 kDa) HA-tagged prod-
ucts; L2 inactive intein and L2 linear peptide plasmids produced
only unprocessed and linear peptide (18 kDa) HA-tagged prod-
ucts, respectively; and the L2 active intein plasmid produced
unprocessed and IC domain (17 kDa) HA-tagged products. In
the EY93 yeast strain, L2 active intein processing was slow rela-
tive to the L2 lariat and the unprocessed product migrated
slightly slower in a SDS-PAGE gel. Similar differences in active
L2 intein and L2 lariat processing were also observed in E. coli,
where after IPTG induction 65% of the L2 lariat was correctly
processed, whereas only 19% of the active L2 intein under-
went processing to the lariat intermediate (Figure S2).
We did not detect any interactions between LexA and the L2
inactive intein, the L2 active intein, and the L2 linear peptide or
between L2 scrambled, L2 inverted, and CPGC noose peptide
(pIN01) lariat controls in Y2H assays when the LEU2, ADE2,
and LacZ reporter genes were assayed together (Figure 3B).
Only the L2 lariat interacted with LexA in the Y2H assay when
all reporters were used, which highlighted the importance of
the lactone constraint in this interaction. We detected a weak
interaction between the L2 inactive intein and a very weak inter-
action with the L2 active intein when only the LEU2 reporter gene
was used (Figure S3). The dependence of the interaction on the
lactone constraint was not unique to this anti-LexA lariat as we
have also shown that lactone cyclization was important for lariats
that were isolated against two other target proteins (Figure S4).
We performed an alanine scan to determine amino acids
important for the interaction of the L2 lariat with LexA (Figure 3C).
All of the alanine mutants except for L2 E9A did not interact with
LexA. Glutamic acid at position 9 has been proposed to facilitate
production of cyclic peptides from an active intein (Scott et al.,
2001; Naumann et al., 2005). The E9A mutation is still active in
the Y2H assay, suggesting that E9 does not contribute to the
L2 lariat interaction with LexA and is not required to produce
the lariat. Interestingly, we found that the L2 E9A mutation re-
sulted in better lariat stability (Figure S5).
We also analyzed the ability of the L2 lariat to interact with two
LexA mutants, S119A and K156A. LexA exists in either a non-
cleavable (NC) or cleavable (C) conformation, where the C
conformation accounts for <0.1% of the LexA population at pH
7 (Roland et al., 1992). Luo et al. (2001) proposed that RecA157, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1149
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Figure 1. Production and Isolation of Anti-LexA Lariats
(A) Intein-mediated peptide cyclization. (i) Unprocessed intein undergoes an N-to-S acyl shift using the IN+1 cysteine at the peptide-IN junction. (ii) Transesteri-
fication reaction involving IC+1 serine at the IC-peptide junction and the thioester formed in step (i), which releases the IN domain and produces the lariat inter-
mediate. (iii) IC-1 asparagine undergoes a side chain cyclization, which releases the IC domain and generates a lactone-cyclized peptide. (iv) Lactone-cyclized
peptide undergoes a thermodynamically favored O to N acyl shift to produce a lactam-cyclized peptide.
(B) Lariat-producing intein. The lariat is produced by mutating the asparagine at position IC-1 to alanine (*), which inhibits asparagine cyclization and stops the
reaction at the lariat intermediate.
(C) The LexA-lariat Y2H assay. The LexA operator (LexAop) is upstreamof stably integrated Y2H reporter genes. Plasmid pEG202 expresses LexA, which binds to
the LexAop. Plasmid pIL-XX expresses members of the lariat library that contain and IC domain fused to an N terminus HA tag, a transcription activation domain
(ACT), and a nuclear localization sequence (NLS). X represents amino acids coded by the NNK codon. E and Y represent constant glutamate and tyrosine amino
acids. Lariats that interact with LexA bring the transcription activation domain near the transcription start sites of the reporter genes and activate transcription.
(D) Amino acid sequences of the noose region from two anti-LexA lariat peptides (L1 and L2). Amino acids from the combinatorial region are bolded and dashes
are used to align common amino acids in L1 and L2.
1150 Chemistry & Biology 16, 1148–1157, November 25, 2009 ª2009 Elsevier Ltd All rights reserved
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toward the C conformation. LexA S119A mutant has a change
in the active site serine nucleophile that prevents cleavage (Sli-
laty and Little, 1987), but does not alter the NC conformation
(Luo et al., 2001). LexA K156A mutant has a change in the active
site lysine general base that prevents cleavage and shifts the
equilibrium toward the C conformation (Luo et al., 2001). The
L2 lariat interacted with LexA and LexA K156A but not with
LexA S119A (Figure 3D), which suggested that the L2 lariat inter-
acted near the LexA autoproteolysis active site.
We used surface plasmon resonance (SPR) to determine the
dissociation constant (KD) between LexA and a synthetic L2 lariat
peptide (Figure 3E). An L2 lariat peptide was synthesized with an
alanine and biotin moiety on the N terminus ‘‘tail,’’ which
replaces the IC domain in the L2 lariat. The synthetic L2 lariat in-
teracted with LexA with a KD of 37 mM. In contrast, we were
unable to detect binding between LexA and the synthetic bioti-
nylated linear L2 peptide at concentrations up to 125 mM (Fig-
ure S6). The in vitro binding constant may differ from the
in vivo binding constant since the L2 lariat may interact with a
specific chromosome-associated conformation of LexA. In E.
coli, 20% of LexA is free in solution with the majority of LexA
associated with DNA (Sassanfar and Roberts, 1990). Further,
structural modeling and biochemical studies suggest that LexA
undergoes a conformational change when it binds its operator
(Butala et al., 2007; Chattopadhyaya and Pal, 2004; Groban
et al., 2005). It is conceivable that the KD of the L2 lariat could
be decreased further by affinitymaturation using amore stringent
Y2H screen. Previously, Colas et al. (2000) used random PCR
mutagenesis and a single operator LexA Y2H LacZ reporter to
enhance theaffinityof ananti-Cdk2aptamer from100nMto5nM.
The lexA promoter contains several tandem LexA operators
(Little et al., 1981; Brent and Ptashne, 1981) and LexA expression
is autoregulated by a feedback mechanism (Little and Harper,
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The L2 active intein contains Asn at position IC-1 and Cys at position IN+1, which
are necessary to produce the lactam-cyclized peptide. The L2 lariat contains
an asparagine to alanine mutation at position IC-1, which blocks the asparagine
side chain cyclization reaction. The L2 inactive intein contains the same muta-
tions as the lariat and a cysteine to alanine mutation at position IN+1. The
cysteine to alanine mutation at IN+1 blocks the N to S acyl shift. The L2 linear
peptide contains two stop codons at the IN+1 position. L2 scrambled and L2
inverted are the same as the L2 lariat except that the L2 peptide sequence
is rearranged or inverted, respectively. pIN01 intein is an inactive intein with
a CGPC peptide noose.Chemistry & Biology 16, 1148–111979). To investigate whether L2 lariat was associated the lexA
promoter, we used a Ni2+-nitriloacetic acid (Ni2+-NTA) chromatin
precipitationandquantitativePCRassaywithHis-taggedL2 lariat
and Ni2+-NTA affinity chromatography (Tamimi et al., 2004). The
L2 lariat showed an 5-fold greater association with the lexA
promoter compared to the L2 scrambled lariat (Figure 3F).
We used LC-ESI-TOF mass spectrometry (MS) to determine
whether the L2 lariat was stably expressed from a His tag bacte-
rial expression plasmid (pETIL-L2) in BL21CodonPlus (BL21-CP)
E. coli. After purification of the L2 lariat using a Ni2+-NTA column,
we observed two products near the calculated molecular weight
of the L2 lariat. The lighter product (8651Da) corresponded to the
L2 lariat, which represented 26% of the total product, and the
heavier product (8669 Da) corresponded to a hydrolyzed lariat
product, which represented 74%of the total product (Figure 4A).
PreviousMS studies on the cyclic peptide-producing intein reac-
tion have reported the lariat intermediate as present mainly in the
hydrolyzed form (Scott et al., 1999, 2001). Together these results
suggest that hydrolysis of the lactone bond may be caused by
high temperatures and acidic conditions used in theMS analysis.
To determine the amount of lariat present prior to MS analysis,
we forced the cleavage of the lariat lactone using Na18OH (Hage-
lin, 2005), digested the lariat with trypsin, and analyzed the
molecularweight of fragments using LC-ESI-TOFMS (Figure 4B).
Lariat lactones cleaved by Na18OH were 2 Da heavier than
lactones cleaved prior to Na18OH treatment. We observed incor-
poration of 18O into two trypsin fragments that resulted either
from hydrolysis of the lactone bond or from an a-H elimination
that generated dehydroalanine, which was followed by aMichael
addition (Figure S7). The fraction of 18O incorporated in these
fragments indicated that 46% of the lariat was cyclized prior to
MS analysis (Figure S8). This value represented a low estimate
of the amount of L2 lariat present in E. coli as some of the lariat
may have been hydrolyzed during Ni2+-NTA affinity chromatog-
raphy and reverse-phase HPLC purification and lyophilization
prior to being hydrolyzed by Na18OH. These data, combined
with the fact that many lactone-cyclized peptides exist in nature
(Gru¨newald and Marahiel, 2006), support the existence of the
lariat structure in vivo.
Despite the observation that a significant portion of the lariat
was hydrolyzed, we were still able to isolate lariats that activated
the reporter genes in the Y2H assay. Since activation of Y2H
reporters depends on a variety of parameters including protein
expression levels, interaction strength, and the threshold for
reporter activation, it is difficult to predict whether this level of
cyclization would be sufficient for other targets. Other applica-
tions may require pure lariat populations and in these cases it
maybepossible togeneratemorestable lariats aswehaveshown
that the lariat fraction can be enhanced by mutations to the lariat
noose region. For example, the L2 E9A mutant was present as
61% lariat in E. coli compared to L2 lariat, which was present
at 26% lariat. These values represent a low estimate of the
amount of lariat present sincewedidnot correct themfor the lariat
that was hydrolyzed during the MS analysis (Figure S5).
Activity of Anti-LexA L2 Lariat
We monitored the ability of the L2 lariat to inhibit MMC-induced
depletion of LexA at the lexA promoter using chromatin immuno-
precipitation (ChIP) and quantitative PCR (Wade et al., 2005)57, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1151
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(A) Western analysis of L2 lariat and intein processing in
EY93 using an anti-HA antibody. The HA-tagged L2 inac-
tive intein is 32 kDa. The L2 lariat, L2 scrambled lariat,
and L2 inverted lariat produced two products, an HA-
tagged unprocessed lariat intein and an HA-tagged lariat,
which are 32 kDa and 18 kDa, respectively. The HA-
tagged L2 linear peptide is 18 kDa. The L2 active intein
produced two products, anHA-tagged unprocessed intein
and an HA-tagged IC domain, which are32 kDa and17
kDa, respectively. In SDS-PAGE, the unprocessed active
intein runs at a slightly higher molecular weight. MW repre-
sents molecular weight markers (kDa).
(B) Y2H analysis of the interaction of LexA with L2 lariat
and intein constructs. pIN01 is an inactive lariat expression
plasmid that expresses an inactive intein with a CGPC
peptide noose. (i) Yeast growth on nonselective synthetic
dextrose (SD) His and Trp media. (ii) Yeast growth on
SGR His, Trp, Leu, Ade, and X-Gal media, which
selects for the activation of LEU2, ADE2, and LacZ Y2H
reporter genes.
(C) Y2H analysis of the interaction of LexA with L2 lariat
and L2 lariat alanine mutants. Yeast were grown on SGR
His, Trp, Leu, Ade, and X-Gal media that selects for
the activation of LEU2, ADE2, and LacZ Y2H reporter
genes. Con represents L2 scrambled lariat.
(D) Y2H analysis of the interaction of L2 lariat and LexA and
LexA mutants. Yeast were grown on SGR His, Trp,
Leu, Ade, and X-Gal media that selects for the activation
of LEU2, ADE2, and LacZ Y2H reporter genes. Con repre-
sents L2 scrambled lariat.
(E) SPR analysis of L2 Lariat-LexA interaction. Maximum
SPR response units were calculated for L2 lariat concen-
trations ranging from 7.8 mM to 125 mM. The binding
isotherm was fit to a one site binding model to calculate
the KD ± standard error using Prism4.0 (GraphPad) statis-
tical software. Representative SPR sensograms are
shown in Figure S6. Error bars represent the standard
deviation from three independent experiments.
(F) Analysis of the association of the L2 and L2 scrambled
lariats with the lexA promoter using Ni2+-NTA chromatin
precipitation assay. Precipitated lexA promoter DNA was
quantified by real-time PCR and normalized to the corre-
sponding input DNA. Histograms show the ratio of Ni2+-
NTA precipitated lexA promoter DNA (lariat-lexA complex)
between IPTG-induced and uninduced His-tagged L2 and
L2 scrambled lariats. Error bars represent the standard
deviation from three independent experiments. **p < 0.01
between L2 lariat and L2 scrambled lariat.(Figure 5A). MMC is a potent inducer of bacterial SOS response
that causes the release of LexA from its promoter (Lin and Little,
1988). We observed that MMC treatment depleted 94% of LexA
from the lexA promoter in cells expressing the L2 scrambled
lariat control, whereas only 14% of LexA was depleted in cells
expressing the L2 lariat. Expression of L2 active intein, L2 inac-
tive intein, and L2 linear peptide resulted in 73%, 86%, and
88% of LexA being depleted from lexA promoter after MMC
treatment, respectively.
Wemonitored the ability of the L2 lariat to blockMMC-induced
LexA autoproteolysis using western analysis with an anti-LexA
antibody. MMC activates RecA coprotease activity and induces
cleavage of LexA (Lin and Little, 1988). We monitored degrada-
tion of LexA after exposure to MMC (Yasuda et al., 1998) in the
presence and absence of L2 lariat, L2 scrambled lariat, L2 linearpeptide, L2 inactive intein, and L2 active intein (Figure 5B). We
observed that LexA was significantly degraded (98%) after 1 hr
treatment with MMC in cells expressing L2 scrambled control.
In contrast, the L2 lariat completely blocked MMC-induced
LexA degradation. L2 linear peptide, L2 active intein, and L2
inactive intein partially blocked MMC-induced LexA proteolysis
with 87%, 65%, and 67% of LexA remaining, respectively.
We tested the ability of L2 lariat to inhibit E. coli growth in the
presence of MMC using the survival assay described by Lin and
Little (1988). We expressed L2 scrambled lariat, L2 lariat, L2
linear peptide, L2 inactive intein, and L2 active intein in BL21-
CP cells; exposed the bacteria to MMC in 0.85% NaCl for 1 hr;
and assayed their survival (Figure 6). Expression of the L2 lariat
enhanced the activity of MMC and reduced BL21-CP cell
viability to 30% relative to the L2 scrambled lariat. Expressionll rights reserved
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(A) ESI-TOF MS analysis of His tag purified L2 lariat produced in BL21-C P. L2 lariat (8651.7 calc; 8651.4 obs) and hydrolyzed L2 lariat (8669.7 calc; 8669.5 obs).
(B) Analysis of the amount of lariat present prior toMS analysis. (i) Lariat cyclized through a lactone bond. (ii) Lariat cleaved prior to Na18OH treatment. (iii) Products
from the Na18OH-induced cleavage of lactone bond. (iv) Trypsin digest of the cleaved lariat to confirm the location of 18O incorporation. The percentage of each
fragment containing 18O is shown and corresponds to the amount of lariat cyclized through a lactone bond prior to MS analysis (Figure S8).of L2 linear peptide, L2 active intein, and L2 inactive intein
enhanced the activity of MMC by 68%, 65%, and 53%,
respectively, relative to the L2 scrambled lariat. A possible
reason for the low activity of the L2 active intein in the activity
assays was the low processing of L2 active intein in E. coli rela-
tive to the L2 lariat (Figure S2). The L2 lariat is identical to the L2
active intein except for an asparagine to alaninemutation at posi-
tion IC-1. Asparagine at position IC-1 decreased production of the
lariat intermediate from the active construct; however, it is
required for converting the lariat to a lactam-cyclized peptide,
which suggested that it may be difficult to engineer the active
construct to improve its processing efficiency.
In summary, the L2 lariat had the highest activity in lexA
promoter ChIP, LexA proteolysis, and survival assays. L2 inac-
tive and active constructs showed similar activity in these
assays, which was lower than the L2 lariat and corresponded
with the lower affinity of the L2 inactive intein in the Y2H assay.
Since the L2 active construct does not process well, its activity
is most likely due to the unprocessed product, which is similar
to the L2 inactive product. The L2 linear construct showed the
lowest activity, which corresponds with its inability to activate
reporter genes in the Y2H assay and to show an interaction
with LexA in the SPR assay.
DISCUSSION
We developed a new strategy for displaying cyclic peptides with
a covalently attached linear peptide. The N terminus of the lariatChemistry & Biology 16, 1148–115can be used to fuse protein moieties such as a transcription
activation domain, localization sequence, fluorescent protein,
membrane permeable peptide, etc. Lariats can be produced in
prokaryotic and eukaryotic environments and the noose region
can be used to display combinatorial peptide libraries. Lariats
are constrained by a lactone bond, allowing a variety of peptide
sequences to be displayed. Lactone bonds are stable under
reducing conditions, which allows lariat libraries to be screened
using intracellular assays such as the Y2H assay. This is in
contrast to disulfide bond-constrained peptide libraries, which
are not stable under reducing conditions and must be screened
using in vitro selection strategies such as phage display (McLaff-
erty et al., 1993).
Lariats have advantages over intein-produced lactam-cy-
clized peptides for analyzing intracellular protein function. First,
for Ssp DnaE intein-based constructs, the lariat is produced at
higher levels than its corresponding L2 cyclic peptide. Second,
lariat libraries can be screened using the Y2H assay to isolate
lariats against a target protein. Combinatorial libraries of cyclic
peptides generated by intein-mediated cyclization have been
successfully screened to isolate cyclic peptides that inhibit
protein interactions and activities (Naumann et al., 2008; Horswill
et al., 2004; Tavassoli and Benkovic, 2005; Tavassoli et al., 2008;
Kritzer et al., 2009) and cell phenotypes (Kinsella et al., 2002;
Nilsson et al., 2005). These selection strategies, however, do
not allow cyclic peptides to be targeted to a specific protein.
Here, we have shown that synthetic lariat peptides, which still
retain the same binding activity as the lariat, can be generated7, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1153
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showed that cyclic peptides that inhibit IL-4 signaling in B cells
still retain their activity when they are expressed in a mutated in-
tein construct that does not produce cyclic peptides. Therefore,
it is conceivable that in cases where the lariat cyclic peptide
structure is not dependent on the geometry of the lactone
bond that it should be possible to generate peptides, which
retain the activity of the lariat peptide, that are cyclized through
an amide backbone bond.
In summary, we have presented a new method to isolate lariat
peptides against a given target protein using the Y2H system.
We used lariat peptide Y2H assay to generate lariat inhibitors
of LexA and validate LexA as a therapeutic target for potentiating
the antimicrobial effects of reagents that activate the SOS
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Figure 5. L2 Lariat Inhibition of LexA Autoproteolysis
(A) ChIP analysis of the influence of L2 lariat and intein constructs on MMC-
induced depletion of LexA at the lexA promoter. The percentage of LexA re-
maining bound to the lexA promoter after MMC treatment was measured as
a ratio of the occupancy units of MMC-treated to untreated samplesmultiplied
by 100. Error bars represent the standard deviation from three independent
experiments. **p < 0.01 and *p < 0.05 between L2 lariat and intein constructs
and the L2 scrambled lariat.
(B) Inhibition of MMC-induced LexA cleavage by L2 lariat. BL21-CP cells ex-
pressing L2 lariat and intein constructs were treated with MMC and chloram-
phenicol. Cell extracts were analyzed by western analysis using an anti-LexA
antibody. The percentage of LexA that does not undergo proteolysis after 1 hr
treatment with MMC is reported. Error bars represent the standard deviation
from three independent experiments. **p < 0.01 and *p < 0.05 between L2 lariat
and intein constructs and the L2 scrambled lariat.1154 Chemistry & Biology 16, 1148–1157, November 25, 2009 ª200response pathway. The lariat technology provides a rapid high
throughput assay for isolating peptide inhibitors that can be
used for the reverse analysis of protein function or as drugs or
pseudo-drugs for validating therapeutic targets.
SIGNIFICANCE
Lariat peptides possess desired traits for characterizing
the function and therapeutic potential of proteins. Lariats
consist of a lactone-cyclized peptide with a covalently
attached transcription activation domain. The transcription
activation domain allows combinatorial lariat libraries to
be screened against protein targets using the yeast two-
hybrid assay (Y2H). Combinatorial lariat libraries should in
principle contain members that bind any protein target.
Lariat peptides are constrained by a lactone bond, which
allows them to be used in reducing intracellular environ-
ments. Lariats function as trans dominant inhibitors, which,
unlike genetic approaches that inactivate genes by deletion
or creation of loss-of-function mutations, can be easily used
to inhibit protein function in diploid organisms. Lariats
inhibit their protein target directly and have the potential to
block specific interactions with a protein while leaving other
interactions unperturbed. This is in contrast to trans domi-
nant agents like antisense RNA/DNA, ribozymes, and RNAi
that block transcription and translation of their target.
Thus, results obtained using lariat inhibitors can be used
directly to evaluate the therapeutic potential of inhibiting
targets with small molecule drugs. Lariats can be easily
and rapidly generated against any given target compatible
with the Y2H assay and thus are easier to generate than
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Figure 6. Survival Assay for MMC-Treated BL21-CP Cells Trans-
formed with L2 Lariat and Intein Constructs
Normalized relative cell survival was calculated by dividing the number of cfu
after 30 min MMC treatment by the number of cfu at the zero hour time point.
Error bars represent the standard deviation of five independent experiments.
**p < 0.01 and *p < 0.05 between L2 lariat and intein constructs and the L2
scrambled lariat.9 Elsevier Ltd All rights reserved
Chemistry & Biology
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activation domain of lariats can be replaced by other peptide
and chemical moieties such as affinity tags, fluorescent
molecules, localization sequences, etc., which give them
advantages over ‘‘head-to-tail’’ cyclized peptides, which
have no free end to attach moieties. Together, these proper-
ties make lariats an ideal reagent for assessing whether
small molecules inhibitors can be generated against
a protein target. Further, the small size of lariats makes
them amenable to chemical synthesis and allows their struc-
ture to be easily solved, which makes them useful as poten-
tial drugs or drug leads.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for a detailed description of
plasmid construction, western analysis, intein processing analysis, lariat and
LexA purification, LexA and Ni2+-NTA chromatin precipitation assays, and
LexA proteolysis assay.
Reagents
Oligonucleotides were synthesized by Integrated DNA Technologies and are
listed in Table S1. The biotin-labeled L2 lactone peptide was synthesized by
Protein Peptide Research. The lactone peptide was synthesized on 2-chloro-
trityl resin, using serine(trityl) for the serine to be cyclized. The fully side chain
and N-terminal protected peptide was cleaved from the chlorotrityl resin using
20% trifluorethanol/dichloromethane and then the trityl group was removed
from the side chain of serine using 1% trifluoroacetic acid/dichloromethane.
The peptide was cyclized using benzotriazol-1-yloxy tris(dimethylamino)phos-
phonium hexafluorophosphate/diisopropylethylamine in dichloromethane,
having first solubilized the peptide in a small quantity of dimethylformamide.
Once cyclized the remaining protecting groups were removed using 95% tri-
fluoroacetic acid scavengers. The biotin-labeled linear L2 was synthesized
by GenScript.
Strains and Plasmids
E. coli Strains
BL21(DE3) and BL21-CodonPlus(DE3)-RIL (BL21-CP) were obtained from
Novagen and Stratagene, respectively.
S. cerevisiae Strains
EY93 (MATa ura2 his3 trp1 leu2 ade2::URA3) was derived from EGY42 (Cohen
et al., 1998). EY111 (MATa his3 trp1 ura3::LexA8op-lacZ ade2::URA3-
LexA8op-ADE2 leu2::LexA6op-LEU2) was derived from EGY48 (Golemis
and Brent, 1992).
Plasmids
pEG202
pEG202 expresses the LexA target (GenBank accession U89960) (Gyuris
et al., 1993).
pIN01
pIN01 expresses an inactive Synechocystis spp. strain PCC6803 (Ssp) DnaE
lariat intein construct with a CPGC peptide in the noose region.
Lariat Library (pIL-XX)
We constructed pIL-XX by replacing the CPGC linker peptide in pIN01 with
a combinatorial seven amino acid peptide using oligonucleotide K. The library
was cloned into RsrII-digested pIN01 using in vivo homologous recombination
(Ma et al., 1987) in EY93. We performed 100 lithium acetate transformations
(Schiestl and Gietz, 1989) with each transformation containing 400 ng of
PCR-amplified oligonucleotide K and 1 mg of RsrII-digested pIN01. In total,
20 million yeast colonies were obtained.
pIL-L2
pIL-L2 expresses L2 lariat isolated from the pILXX library. The noose amino
acid sequence of pIL-L2 is RSWDLPGEY.
pIL-L2 Scrambled
pIL-L2-scrambled expresses the L2 scrambled lariat, where the noose amino
acid sequence is DPGLRSWEY. pIL-L2-scrambled was constructed using theChemistry & Biology 16, 1148–115same strategy as pIL-XX, except oligonucleotide S was used in place of oligo-
nucleotide K.
pIL-L2 Inverted
pIL-L2-inverted expresses the L2 inverted lariat where the noose amino acid
sequence is GPLDWSREY. pIL-L2-inverted was constructed using the same
strategy as pIL-XX, except oligonucleotide T was used in place of oligonucle-
otide K.
pIN-L2
pIN-L2 expresses the L2 inactive intein. pIN-L2 was constructed by mutating
cysteine at IN+1 to alanine using PCR site-directed mutagenesis.
pLIN-L2
pLIN-L2 expresses the L2 linear peptide. pLIN-L2 was constructed by intro-
ducing two stop codons at position IN+1 and IN+2 in pIL-L2.
pACT-L2
pACT-L2 expresses the L2 active intein. pACT-L2 was constructed by
mutating alanine at position IC+1 in pIL-L2 to asparagine using PCR site-
directed mutagenesis.
E. coli intein expression plasmids were constructed by PCR amplifying the
entire intein gene including the stop codon from the corresponding yeast
expression vector using primers P and Q. The PCR product was digested
with EcoRI and XhoI (Fermentas) and cloned into pET28b (Novagen) using
standard restriction enzyme-based cloning procedures (Raleigh et al., 2002).
The following E. coli expression plasmids were constructed: pETIL-L2,
expresses L2 lariat; pETIL-L2scrambled, expresses the L2 scrambled lariat;
pETIN-L2, expresses the L2 inactive intein; pETLIN-L2, expresses the L2 linear
peptide; pETACT-L2, expresses the L2 active intein.
Screening Combinatorial Lariat Intein Library
The lariat library was screened for interactions with LexA using Y2H interaction
mating (Kolonin et al., 2000). We transformed the LexA bait plasmid (pEG202)
(Gyuris et al., 1993) into EY111 and mated EY111::pEG202 to EY93::pIL-XX.
EY111::pEG202 was cultured in 500 ml of synthetic dextrose. His media to
an OD600 of 0.6–0.9. EY111::pEG202 cells were pelleted by centrifugation
and resuspended in an equal volume of yeast peptone dextrose (YPD) media.
EY93::pIL-XX cells were mixed with EY111::pEG202 cells at a ratio of 1:20.
Yeast cells were mated on YPD plates at 30C for 24 hr. Mated yeast cells
were pooled and 200 million diploid yeast cells were screened to detect lariats
that interacted with LexA using the LEU2, ADE2, and LacZ reporter genes.
Diploid yeast cells were cultured on synthetic galactose/raffinose (SGR)
His, Trp, Leu, and Ade plates containing X-Gal for approximately 7
days. Positive colonies were selected and positive interactions were recon-
firmed by isolating pILXX from the positive colonies and repeating the Y2H
assay as described above.
Characterization of Intein Processing and Lariat Product
We monitored expression of L2 lariat and intein constructs in EY93 using
western analysis with an anti-HA antibody. Samples were normalized using
their OD600 and 20 ml of supernatant was analyzed by western analysis with
an anti-HA tag antibody (Santa Cruz Biotechnology, Inc.) (1:200 dilution).
The LI-COR Odyssey infrared imaging system (LI-COR Biosciences) was
used to visualize and quantify blots.
We used LC-ESI-TOF MS to confirm the molecular weight of the His-tagged
L2 lariat purified from E. coli. To confirm the presence of the lariat lactone prior
to MS analysis, lyophilized His-tagged L2 lariat, which had been purified using
Ni2+-NTA affinity chromatography and reverse-phase HPLC, were treated with
0.5 M Na18OH. The products were purified using reverse-phase HPLC and di-
gested with trypsin, and the molecular weights of the trypsin fragments were
analyzed using LC-ESI-TOF MS.
Surface Plasmon Resonance Assay
SPR was performed using a BiaCore3000 (BiaCore Life Sciences). LexA was
purified using HIS-Select Nickel affinity gel (Sigma) and diluted in 50 mM
Tris-HCl and 150 mM NaCl prior to use in SPR analysis. Purified His-tagged
LexA was immobilized on a Series S Sensor Chip NTA (BiaCore Life Sciences).
L2 lariat or L2 linear peptides were dissolved in 50 mM Tris-HCl and 150 mM
NaCl. Sequential injections of 2-fold serial dilutions of either synthetic L2 lariat
or L2 linear peptides ranging from 125 mM to 7.8 mM were injected over the
surface at a flow rate of 10 ml/min. The KD for the L2 lariat-LexA interaction7, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1155
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tration and fitting the data to a one site binding model using Prism4.0 (Graph-
Pad) statistical software.
LexA ChIP Assay
The LexA ChIP assay was based on a previously described procedure (Wade
and Struhl, 2004). BL21-CP cells transformed with E. coli lariat expression
plasmids were grown to an OD600 of 0.6 in LB with 50 mg/ml of kanamycin
(LB-KAN) and then induced for 2 hr with 0.2 mM IPTG at 30C. The culture
was split into two samples; one sample was treated with MMC (0.25 mg/ml)
and the other untreated. Both samples were incubated for 1 hr at 30C.
ChIP assays were performed as previously described (Wade and Struhl,
2004). Eluted lexA promoter DNA was quantified by real-time PCR. The occu-
pancy of LexA at lexA promoter was measured as a ratio of binding of LexA to
the lexA promoter and to a control region in the sgrR (yabN) gene (occupancy
units).
Ni2+-NTA Chromatin Precipitation Assay
Ni2+-NTA chromatin precipitation assay was based on a previously described
procedure (Tamimi et al., 2004). BL21-CP cells transformed with E. coli lariat
expression plasmids were grown to an OD600 of 0.6 in LB-KAN. Cultures
were either induced for 2 hr with 0.2 mM IPTG at 30C or left uninduced. Chro-
matin was precipitated using the protocol for the LexAChIP assay except Ni2+-
NTA beads were used to precipitate His-tagged L2 and L2 scrambled lariats.
Eluted lexA promoter DNA was quantified by real-time PCR and normalized to
the corresponding input DNA.
Quantitative Real-Time PCR
Quantitative real-time PCR was performed using iQ SYBR Green (Bio-Rad) in
a Miniopticon (Bio-Rad). Primers W and X were used to amplify a region of the
lexa gene. Primers Y and Z were used to amplify a region in the sgrR (yabN)
gene. A two step PCR cycle was used with an initial denaturation of 95C for
5 min followed by 95C for 30 s and 61C (lexa) or 59C (sgrR) for 1 min. The
product was amplified for 40 cycles.
Analysis of LexA Autoproteolysis
BL21 cells transformed with E. coli lariat expression plasmids were induced
with 1 mM IPTG and the cells were cultured at 30C to an OD600 0.4–0.6.
Cells were then treated with 100 mg/ml chloramphenicol and the culture was
split in two; one culture was treated with 0.1 mg/ml MMC for 1 hr and the
second culture was left untreated. The cells were lysed and cleared superna-
tants were analyzed by western analysis using an anti-LexA antibody (Invitro-
gen) (1:5000 dilution). The LI-COR Odyssey infrared imaging system (LI-COR
Biosciences) was used to visualize and quantify blots.
Bacterial Viability Assays
We performed cell viability assays as described by Lin and Little (1988). BL21-
CP transformedwith E. coli lariat expression plasmids were cultured at 37C in
LB-KAN to an OD600 of 0.4. The culture was split in two and one sample was
induced with 1 mM IPTG for 1 hr and the other sample was left uninduced. The
samples were diluted 100-fold in 5 ml 0.85% NaCl with or without 0.1 mg/ml
MMC. A 10 ml aliquot was diluted 1000-fold in ice cold LB (1 ml) for a zero
time point control. We incubated the remaining sample at 37C for 30 min
and removed a 10 ml aliquot and diluted it 1000-fold into 1 ml ice-cold LB.
We plated a 60 ml aliquot from the time points on LB plates and incubated
them at 37C overnight. Normalized percent cell survival was calculated by
dividing the number of colony forming units (cfu) after 30 min by the number
of cfu at the zero hour time point.
Statistical Analysis
Data was reported as mean ± standard deviation. P-values were calculated
using a two-tailed t test with Prism 4.0c for Macintosh (GraphPad).
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